Monarch Medical Technologies’ Post

Over the last 18 months, Sepsis Research FEAT has been working on a vitally important project. The aim: to identify the top priorities for sepsis research going forward. Last year we asked you to fill out the first sepsis research priority-setting survey, encouraging you to ask your key unanswered questions about sepsis. This year phase two of this project took a shortlist of survey 1 answers and asked you to rank them in order of their importance to you. Finally, yesterday a workshop of researchers, clinicians and sepsis survivors came together to identify a final top ten list of research priorities. We cannot wait to share its very important findings with our wider community on World Sepsis Day, September 13th. Aberdein Considine #sepsisresearch #JLA #postsepsisoutcomes #newscientificresearch

Measuring outcomes that matter to patients: PIVOTing to Patient-Focused Drug Development in COPD and other chronic lung diseases Patient-Inspired Validation of Outcome Tools

Yetena Weg in collaboration with Ethiopian Society of Internal Medicine presents you: Updates on Approach and Management of Glomerular Diseases By Dr. Nebiyu Getachew (Nephrologist, Assistant Professor of Internal Medicine) 🗓 Date: Apr 27, 2024 🕔 Time: 05:00 PM - 07:00 PM (Ethiopian Time)                  ✨✨✨ 2 CEU Points ✨✨✨ 👉 Click here https://lnkd.in/e-Vf5eSV and REGISTER NOW ! 📩 After registering, you will receive a confirmation email containing information about joining the webinar. #CME   #YetenaWeg   #ESIM

Our new article is now published! This marks my first experience as a correspondent. I invite you all to read and share your thoughts. Your feedback is always appreciated. 🙌 Many thanks to the team! 🔗[https://lnkd.in/dZD5Vxb9] #Article #Publication #IndustryInsights #YourField #ProfessionalGrowth

But My White Count… "I'm concerned about my white blood cells..." In the New England Journal of Medicine [February 15, 2024], Dr. Robin Colgrove, an Infectious Disease consultant, highlights a common concern expressed by patients and even other healthcare providers in requested consults. This concern also relates to the diagnosis of #sepsis based solely on sepsis criteria (sepsis-1, -2, or -3), which can be categorized as "quantitative fallacy." Quantitative fallacy is a prevalent tendency among humans to give excessive importance to easily measurable factors, often overlooking the significance of more nuanced variables. This skewed perspective can lead to an incomplete understanding of complex issues and hinder our ability to make informed decisions. To counteract quantitative fallacy, it is crucial to adopt a big picture view and consider the patient's circumstances, narrative, findings, and clinical course. Examining the complete context allows healthcare providers to connect the dots, identify patterns, and grasp the full scope of the patient's condition. By considering all relevant information, clinicians can make more accurate diagnoses and develop appropriate treatment plans tailored to the individual patient's needs. It is important to note that while sepsis criteria serve as helpful guidelines for early intervention, they are not definitive in determining the presence of sepsis. While these criteria provide valuable indicators, a comprehensive evaluation of the overall context is necessary to make an accurate diagnosis. Relying solely on sepsis criteria can potentially result in underdiagnosis or misdiagnosis. Therefore, healthcare professionals should exercise clinical judgment and consider multiple factors when evaluating a patient for sepsis. #AHIMA #ACDIS #PhysicianAdvisors #ClinicalValidation #ClinicalTruth™ But My White Count… | NEJM, https://lnkd.in/g87jgKjx

43rd #ISICEM: The recordings from our symposium on "Hemoadsorption with CytoSorb® in critically ill patients - Best practice and key learnings" are available in our media center. 📺 Watch “Update on drug removal: More pros than cons”, presented by Dr. Konstanty Szuldrzynski 👉 https://lnkd.in/gnvGbtKq 📺 Watch “Good and bad cytokines in sepsis – Myths and facts”, presented by Prof. Peter Pickkers 👉 https://lnkd.in/gtwwjkFJ #CytoSorbents #Hemoadsorption #CytoSorb

HEART UK is proud to be publishing our new ‘Prevention Pays’ analysis. This analysis brings together publicly available data on the number of avoidable CVD events – such as heart attacks and strokes – and the estimated cost of them to the NHS, to estimate the potential saving to the NHS of reducing them. It also estimates the additional economic gains that could be made by people living longer healthier lives. This analysis highlights that prevention pays. Investing in measures to prevent avoidable CVD events could help unlock precious NHS resource and provide much needed economic gains. Our findings suggest that savings from increased prevention could theoretically be as high as £2 billion. The analysis can be read here, alongside a supporting methodology document which is available upon request. We are excited to be building on this work this year, and plan to use this new analysis to develop a prevention policy paper, due for publication later in the year. Disclaimer: Amarin, Amgen, Daiichi Sankyo and Novartis have contributed to the funding and production of this document which has been written by HEART UK with input from the funding parties. Final editorial control lies with HEART UK.

📰 New publication!   We're pleased to share that Dik Heg of our statistician team has contributed to a recent publication investigating the prevalence of high bleeding risk (HBR) characteristics in real-world settings and assessing the external validity of the MASTER DAPT trial.   The study utilized screening logs to evaluate patient subsets undergoing percutaneous coronary intervention (PCI), revealing insights into HBR prevalence. Out of 2,847 consecutive patients, 1,098 (38.6%) exhibited HBR characteristics, with only 109 (9.9%) consenting for trial participation. 📊   The findings highlight disparities between consecutively screened HBR patients and those selectively included in the trial, suggesting potential selection biases. Find the publication attached to learn more about it! 🧠   #ClinicalResearch #HighBleedingRisk #MASTERDAPT #DCR

In #CTGjournal: Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis (TOUR) Registry Herfarth, et al. ➡️ bit.ly/48LIU0d

Excited to share our recent study, which has evaluated the optimal timing of PCI and TAVI in eligible patients. The results showed that although concomitant PCI and TAVI were accompanied by higher short-term mortality rates, there is no single pattern for all patients and the decision should be made based on individual features. This study provides crucial insights for optimizing treatment approaches in severe AS and CAD cases. A big thanks to the excellent hard worker team [Parisa Fallahtafti, Amirhossein Ghaseminejad-Raeini, Elaheh Karimi, Mahshad Sabri, Mehdi Mehrani, Homa Taheri, Robert Siegel, Neeraj Shah, Michael Nanna, Diaa Hakim] and genius PIs Dr. Kaveh Hosseini and Hamidreza Soleimani.